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Abstract 
Background  
Type 2 diabetic elderly women are at increased risk for osteoporotic fractures. Low levels of 
vitamin D increases this risk. We aimed to measure levels of 25 hydroxy vitamin D (25 OH-D) in 
these patients to help assess the level of risk.  
Patients and Methods 
In this cross sectional case-control study, the serum concentrations of 25 OH-D were measured 
by high performance liquid chromatography (HPLC) in 60 ambulatory, postmenopausal, type 2 
diabetic female patients under oral anti-diabetic treatment. Thirty control females were 
comparable for weight, age and years since menopause. Calcium and Vitamin D intake 
(obtained by 24 hour dietary recall), sun exposure, parathyroid hormone (PTH), serum calcium, 
phosphorus and alkaline phosphatase were also assessed. 
Results 
 The prevalence of 25 OH-D insufficiency was significantly higher in diabetic patients than in 
control subjects (38.3% vs. 20%, p<0.01). About 13% of diabetics with vitamin D insufficiency 
had high PTH levels. While most of the control group with 25 OH-D insufficiency had elevated 
PTH levels. Out of 66 diabetic women, only 11.7% had adequate vitamin D intake and 30% had 
adequate calcium intake. Similarly, in non-diabetic women, only 13.3% had adequate vitamin D 
intake and 26.7% had adequate calcium intake. However, a highly significantly percentage of 
diabetic women (43.4%) with inadequate vitamin D intake develop vitamin D insufficiency 
compared with non-diabetic women (23.1%) (p<0.001). Diabetic patients with 25 OH-D 
insufficiency tend to be older, with higher BMI, and HBA1C (P<0.01, <0.01, <0.001 respectively).  
Conclusion: We documented increased risk of vitamin D insufficiency in type 2 diabetic 
postmenopausal women in the face of inadequate dietary vitamin D and low sun exposure. This 
finding might partially explain the increased risk for osteoporosis among this group and 
warrants consideration of dietary vitamin D supplementation. 
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Introduction 
 
 itamin D deficiency has long been 
recognized as a cause of rickets in 
children and osteomalacia in adults. 
More recent is the awareness of a 
preclinical phase of vitamin D 
deficiency, known as vitamin D 
Insufficiency (< 16 ug/L)1. More recent  
researchers suggest that PTH levels and 
calcium absorption are not optimized 
until serum 25 hydroxy vitamin D (25 
OH-D) levels reach above 40 Pg/L that 
is the "desirable" level and they consider 
levels between 20 and 40 Pg/L as 
sufficient, between 10 and 20 Pg/L as 
insufficient and less than 10 Pg/L as 
deficient2.  
Despite the lack of symptoms, it is likely 
that vitamin D insufficiency has 
deleterious effects on calcium 
metabolism and ultimately the skeleton. 
Vitamin D insufficiency is being 
increasingly recognized as a common 
yet easily modifiable risk factor for 
osteoporosis and could explain the 
deranged mineral homeostasis and 
skeletal morphology with increased risk 
of osteoporotic fracture observed in 
diabetics3.  
In addition, accumulating research 
suggests that low 25(OH)D 
concentrations may be inversely 
associated with impaired glucose 
tolerance4, type 2 diabetes5, metabolic 
syndrome6,7, insulin resistance8,9, and 
cardiovascular disease (CVD)10. 
Additionally, low vitamin D 
concentrations result in elevations of 
parathyroid hormone, which has been 
linked to insulin resistance11-12.  
The mechanisms by which vitamin D 
may affect the risk of type 2 diabetes are 
not clear. The finding of vitamin D 
receptors in ß-cells 13 and the finding of 
impaired insulin secretory capacity in 
mice lacking a functional vitamin D 
receptor14 indicate an important role for 
vitamin D in regulating ß-cell function.  
In a recent large prospective study , a 
potential beneficial role for both vitamin 
D and calcium intake in reducing the 
risk of type 2 diabetes was suggested15. 
However, other short-term intervention 
studies with vitamin D supplementation 
have shown conflicting results 16-19. 
Vitamin D insufficiency is common in 
general medical patients, including 
those without apparent risk factors for 
vitamin D deficiency20 and even in 
young women in sunny countries21. 
Therefore, the association between Type 
2 diabetes and vitamin D insufficiency 
may be just a coincidence and it is still 
not clear if patients with diabetes 
actually differ from non diabetics 
concerning this common state of 
vitamin D insufficiency.  
Based on these findings, we proposed 
that type 2 diabetes mellitus may be 
considered as a risk factor for vitamin D 
insufficiency. As a means of testing this 
hypothesis, and because circulating 
25(OH)D is the hallmark for 
determining vitamin D status, the aim 
of our study was to measure the levels 
of 25(OH)D and dietary vitamin D and 
calcium in a case-control cross-sectional 
protocol involving the ambulatory 
postmenopausal women with type 2 
diabetes to assess the prevalence and 
predictors of vitamin D insufficiency in 
these patients and in comparable non-
diabetic healthy women.  
 
Patients and Methods 
 
Patients study design 
In this cross-sectional case-control 
study, 60 female patients with Type 
2diabetes were recruited from the Out-
patient Department of Kaser Al Eni 
Hospital, Cairo University, during 2 
years period from February 2004 till 
V 
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March 2006. All participants gave a 
written consent to participate in this 
study.  
Samples were withdrawn during 
summer period. Patients were divided 
into 2 groups: group 1 with normal and 
group 2 with insufficient-D level. 
Concerning treatment, 43 were under 
metformin and glibenclamide, 6 were 
under rosiglitazone and metformin and 
11 were under glibenclamide only. 
Thirty age, weight and years since 
menopause matched healthy females 
who were randomly recruited from the 
same hospital were selected as the 
control group. All subjects gave 
informed consent to participate in this 
study. 
 
Inclusion criteria 
Because diabetic elderly women have 
the greatest risk to develop osteoporotic 
fractures, postmenopausal ambulatory 
females under oral antidiabetic-
treatment and with normal renal 
function were selected.  
 
Exclusion criteria 
Patients under insulin therapy or with 
known causes for hypovitaminosis D as 
diabetic nephropathy, nephrotic 
syndrome from any other cause, chronic 
renal failure, chronic liver disease, and 
malabsorption were excluded. Those 
who were taking medications known to 
alter vitamin D metabolism as 
antiepileptics or under any active 
treatment affecting bone as calcium 
supplements, vitamin D, or 
multivitamins except vitamin B, 
corticosteroides, bisphosphonate, and 
patients with bone fractures, metastatic 
bone lesions, immobilization, or other 
severe illnesses (e.g. liver, or heart 
failure) were also excluded from the 
study.  
For   every   patient,   detailed    clinical 
history and examination were 
performed with special emphasis to the 
following points: 
 
Assessment of sun exposure  
Participants were asked how often on 
average they had been exposed to 
sunshine during the day. Sun exposure 
was considered negative if the person 
avoid outdoors during day hours most 
days and positive if he was outdoor for 
Gays per week on average. 
 
Assessment of dietary intake 
Dietary intake was assessed with the 24-
hour dietary recall method. Dietary 
intake of vitamin D and calcium was 
calculated by multiplying the frequency 
of consumption of each food item with 
the nutrient content of each food22. 
 
Assessment of body mass index (BMI)  
BMI was calculated as: Weight /Height2
(Kg/m2). BMI values were applied to the 
related patients for further analysis of the 
retrieved data and the age and sex 
matched groups were studied.
Assessment of diabetic complications 
The presence of microvascular or 
macrovascualr complications was 
confirmed by file review, medical 
history and examination, and vascular 
laboratory studies. 
Chemical assays 
All blood samples were fasting morning 
samples. Fasting blood glucose, serum 
creatinine, calcium, phosphate and 
alkaline phosphatase were measured by 
standard biochemical methods. 
Haemoglobin A1c (HbA1c) was 
determined by HPLC to assess diabetes 
control (normal below 6.1%).  
PTH analysis were determined by solid-
phase two site chemiluminescent 
enzyme immunometric assay, 
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performed on immulite auto analyses 
using kit supplied by DPC (Diagnostic 
Product Corporation, 5700 west 96th 
street, USA). High PTH was considered 
if its level was >60 pg/ml).  
Plasma 25 OH-D was measured 
according to Chromosystem reagent kit 
for high performance liquid 
chromatography (HPLC). Plasma levels 
from 21 to 40 Pg/L were considered 
sufficient, from 10 to 20 ng/ml 
insufficient and <10 Pg/L as deficient2. 
Statistical methods 
Statistical evaluation of all data was 
done on IBM-PC microprocessor 
computer using SPSS software for 
windows (Statistical Package for Social 
Sciences version 13, USA) for data 
management and analysis and the 
Microsoft power point for charts. 
Quantitative data were presented as 
mean ± SD. Data are means ± SD or 
frequencies. Skewed variables were 
logarithmically transformed to improve 
normality before analysis. For the 
comparison of the three groups’ means, 
one way analysis of variance (ANOVA) 
was used followed by Students' 
Newman Keuls test to detect significant 
difference. All tests were two tailed and 
considered significant when p<0.05. The 
coefficients of correlation between 
different studied parameters were 
calculated according to Pearson’s 
method. 
 
Results 
Figure 1 shows that the prevalence of 
25–OH insufficiency (10-20Pg/L) was 
significantly higher in diabetic patients 
than in control subjects (38.3%23) Vs 
(20% 6), p<0.01.  
 No cases of vitamin D–deficiency 
(<10Pg/L) were detected. Figure 1 also 
shows the relation between vitamin D 
insufficiency and high PTH (>60 
pg/ml). About 13% (3 out of 23) of 
diabetics with vitamin D insufficiency 
had PTH levels above normal range(>6o 
Pg/ml). While most of the control group 
with 25 OH-D insufficiency (83.3% (5 
out of 6)) had elevated PTH.  
 
 
 
Figure 1: Prevalence % of vitamin D 
insufficiency in control and patient groups in 
relation to high PTH
 
Figure 2: Prevalence of vitamin D 
insufficiency in control and patient groups in 
relation to vitamin D intake 
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In Figure 2, based on the latest 
guidelines set by the Institute of 
Medicine23, out of the sixty diabetic 
women, only 11.7% (7) had adequate
vitamin D intake ( 400 IU/day), and 
30% (18) had adequate calcium intake (
1,200 mg/day). Similarly, in the thirty 
non-diabetic women, only 13.3% (4) had 
adequate vitamin D intake and 26.7% (8) 
had adequate calcium intake. However 
a significant percentage of diabetic 
women (43.4%; 23 out of 53) with 
inadequate vitamin D intake develop 
vitamin D insufficiency compared with 
non-diabetic women 23.1% (6 out of 26) 
(p<0.001). 
 
According to serum level of 25 OH-D, 
diabetics were divided into 2 groups. 
Table 1 shows comparison between 
control and diabetic groups. The mean 
level of 25 OH-D was desirable in the 
control group (53.4±4.3 Pg/L), sufficient 
in diabetic group 1 (33.7±3.8 Pg/L) with 
normal PTH level (27.1±1.78 pg/ml) and 
insufficient in diabetic group 2 (13.1±0.9 
Pg/L) with significantly higher PTH 
(48.3±8.41 pg/ml) (p<0.001 for all)  
(Table 1). However, the mean PTH in 
this group was not above normal limit 
(>60 pg/ml). 
 
Despite the fact that the control group 
was selected to be age and weight-
matched to the diabetic patients, 
diabetic group 2 was found to be 
significantly older (67.2±1.3 years) than 
other 2 groups (64.6± 1.7 years for 
control group and 59.7±3.1 years for 
diabetic group 1) (p<0.05 for both) with 
higher BMI (29.4±3.5 Kg/m² vs 25.8±2.4 
& 26.3±1.4 Kg/m² for controls and 
group 1 respectively) (p<0.05 for all).  
In Table 1, 11 diabetic patients from 
group 1 (31.4 %) had microvascular 
complications and 4 patients (11.4%) 
had macrovascular complications. 
While, the frequency of vascular 
complication was significantly higher in 
group 2 with insufficient 25 OH-D {19 
patients (67%) with microvascular and 
11 patients (44%) with macrovascular} 
(p<0.001 for both). 
 
Generally, most of the studied women 
avoid sun exposure during the day and 
spend most of their time indoors. 
Frequency of sun exposure was 
significantly lower in vitamin D 
insufficiency group 2 (21.7%) than in 
normal vitamin D group 1 (28.57%) or 
control group (30%) (p<0.05)  (Table 1). 
In Table 1, the diabetic group 2 with 
vitamin D insufficiency had 
insignificant lower dietary vitamin D 
(291.23±56.45 IU/day) and calcium 
intake (640.3±53.2 mg/day) compared 
with both diabetic group with normal 25 
OH-D (319.17± 21.85 IU/day and 
654±38.9 mg/day respectively) or 
control group (342.70± 45.90 IU/day & 
646.7±40.2 mg/day respectively) (P>0.05 
for all). 
 
As shown in Table 1, both diabetic 
groups showed poor diabetic control 
(significantly high FBG, and HbA1C), 
more evident in the group 2 with 
vitamin D insufficiency. This group also 
showed as expected significantly  lower  
calcium  and phosphorous  and  higher  
alkaline  phosphatase  levels (8.8 ±0.15, 
2.8± 0.8 & 160.2±32.1 mg/dl  
respectively) compared with the other 
groups (9.71 ± 0.1 , 4.1±0.7, 134.8±17.8, 
27.1±1.78 mg/dl respectively for 
diabetic group 2 and 9.86± 1.9, 4.3 ± 0.9, 
131 ± 15.4 respectively for control 
group). 
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Table 1:  Comparison between control and both diabetic groups
 
 
Characteristics 
 
 
 
 
Control 
group n=30 
Group 1 
Type 2 diabetic 
females with 
sufficient 25 OH-D  
(21-40 Pg/l) 
n=37 
Group 2 
Type 2 diabetic females 
with insufficient 25 OH- D 
(10-20Pg/l) 
n=23 
 
 
P-value 
Age (years) 64.6± 1.7 59.7±3.1 67.2±1.3 p1>0.05^ 
p2<0.05* 
p3<0.05*
BMI (Kg/m²) 25.8±2.4 26.3±1.4 29.4±3.5 p1>0.05^ 
p2<0.05* 
p3<0.05* 
Duration of DM 
(years)
------------ 15±2.1 16±1.5 p3>0.05^ 
Frequency of 
Complications 
Microvascular: % 
Macrovascular: % 
-------------  
31.4 (11)% 
11.4 (4)% 
 
67% (19) 
44% (11) 
 
p3<0.001** 
p3<0.001** 
Frequency of sun 
exposure (%) 
30% (9) 28.57% (10) 21.7% (5) p1>0.05^ 
p2,0.05* 
p3<0.05* 
Vitamin-D intake 
(IU/day) 
342.70±45.90 319.17± 21.85 291.23±56.45 #>0.05^
Calcium intake 
(mg/day) 
646.7±40.2 654±38.9 640.3±53.2 #>0.05^
FBG (mg/dl) 74.6±13.0 178.7±51.8 210.5±45.8 p1<0.001** 
p2<0.001** 
p3<0.05*
HbA1c  5.3±0.5 8.3±1.2 10.1±1.3 p1<0.001** 
p2<0.001** 
p3<0.01* 
Calcium (mg/dl) 9.86± 1.9 9.71 ± 0.1  8.8 ± 0.15 p1>0.05^ 
p2<0.05*
p3<0.05* 
Phosphorus 
(mg/dl) 
4.3 ± 0.9 4.1±0.7 2.8± 0.8 p1>0.05^ 
p2<0.001* 
p3<0.001* 
ALP (mg/dl) 131 ± 15.4 134.8±17.8 160.2±32.1  p1>0.05^ 
p2<0.05* 
p3<0.05* 
PTH (Pg/ml)  28.1± 2.60 27.1±1.78 48.3±8.41 p1>0.05^ 
p2<0.05* 
p3<0.05* 
25 OH-D (Pg/l) 53.4±4.3 33.7±3.8  13.1±0.9 p1<0.05* 
p2<0.001**  
p3<0.001** 
BMI: body mass index, FBG: fasting blood glucose, HBA1C: glycosylated hemoglobin, ALP: total alkaline 
phosphatase, PTH: Parathyroid hormone, 25 OH-D: 25 hydroxy vitamin D. P1: Comparison between 
control group and diabetic group with normal vitamin D. P2: Comparison between control group and 
diabetic group with low vitamin D. P3: Comparison between diabetic group with normal and group with 
low vitamin D. #: if p1, p2 & p3. are similar. ^:not significant, *: Significant, **: Highly significant. Normal 
serum calcium 8.4-10.2 mg/dl. serum phosphorus  2.5-4.6 mg/dl, PTH: 10-60 Pg/ml.  
Adequate vitamin D intake ( 400 IU/day), calcium intake ( 1,200 mg/day).
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Table 2: Odd ratio of Vitamin D insufficiency  
Characteristics 25-OH D insufficiency 
(10-20 Pg/L) 
Normal 25 OH-D Odd ratio
Patients with diabetes 23/60 
38.3% A 
37/60 
61.7% B 
2.49 
p<0.01 
Non-diabetic controls 6/30 
20%  C 
24/30 
80% D 
Odd ratio= (A/C)/(B/D)
There were negative correlations 
between 25 OH-D and age (r=- 0.41,  
p<0.01, BMI (r=- 0.40,  p<0.01), and 
HBA1C  (r=- 0.51 p<0.001) (data are not 
shown). Table 2 shows that the Odds 
ratio (OR) of vitamin D insufficiency 
was 2.49; meaning that a patient who 
has Vitamin D insufficiency is about 
2.49 times more likely to have type 2 
diabetes than a patient who has not 
Vitamin D insufficiency (OR= 2.49). 
Discussion 
We documented a high prevalence of 
vitamin D insufficiency in the 
postmenopausal ambulatory diabetic 
patients in the face of inadequate 
dietary vitamin D and low sun exposure 
and tendency not detected in a 
comparable non diabetic women (Tables 
1&2). Several studies have 
demonstrated abnormalities in calcium,
phosphate, and vitamin D metabolism 
in diabetic patients. In particular, Isaia 
and co-workers24  who studied similar 
group of patients and both Di-Cesar25
and Pietschmann and their associates26
concluded that Vitamin D deficiency is 
more common in Type 2 than in Type 1 
diabetes.  
While others found that the balance 
among the major vitamin D metabolites 
is altered in diabetes and found that low 
24,25-dihydroxyvitamin D is the altered 
metabolite   in   diabetes27 . Others 
 described variations of vitamin D 
metabolism to include the decreased 
synthesis of vitamin D-binding protein  
by the liver, decreased renal 1 -
hydroxylase activity, and reduced 
vitamin D-receptor concentrations 
resulting in a state of peripheral vitamin 
D resistance28. On the other hand, 
normal 25-hydroxyvitamin D levels was 
detected in some other studies in 
diabetic patients29. 
As a rule, serum PTH increases 
progressively when 25 OH-D falls <30 
Pg/L29. In this study, although mean 
PTH was increased in the group with 
low serum 25OH-D (Table 1), PTH was 
not a sensitive marker of vitamin D 
insufficiency, as only 13% of diabetics 
with vitamin D insufficiency had PTH 
levels above normal range in contrast to 
most control group (Figure 1). This is 
consistent with others30-33, who found 
that PTH secretion seems to be lower 
than expected for the homeostatic needs 
in diabetes. This state of  functional 
hypoparathyroidism  has been 
confirmed by dynamic challenge 
studies, such as during citrate induced 
hypocalcemia,30 or hyperinsulinemic 
hypoglycemia,31 or following an oral 
glucose tolerance test32. This functional 
state has been related to magnesium 
deficiency33 and has been considered 
responsible for the low bone turnover 
that ends in low bone resorption with 
increased bone minaeral density (BMD) 
seen in type 2 diabetes relative to non-
diabetics34. This state has also been 
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reported to be correlated with the 
duration of diabetes and the degree of 
hyperglycemia suggesting that 
hyperglycemia per se may have an 
inhibitory action on the synthesis of 
PTH in diabetes.35 This study confirmed 
the importance of age as a major 
determinant of vitamin D status. Results 
showed that the diabetic group with 
vitamin D insufficiency was older than 
other groups (Table 1) and increasing 
age was negatively correlated with 
levels of 25 OH-D. Declining levels of 25 
OH-D with age have been attributed to 
impaired vitamin D absorption from the 
intestine36, as well as a decline in the 
concentration of the vitamin D 
precursors that are normally stored in 
the skin37. Overall, the elderly have 
reduced capacity to synthesize vitamin 
D in the skin when exposed to UVB 
radiation, and are more likely to stay 
indoors or use sunscreen.37  
Results emphasized also the role of sun 
exposure as vitamin D intake did not 
differ between the 2 diabetic groups, 
however the group with lower sun 
exposure develop hypovitaminosis D 
(Table 1). In addition our studied 
women were well covered with 
excessive wrapping while outdoors. 
Osteomalacia has been documented in 
women who cover all of their skin 
whenever they are outside for religious  
or cultural reasons.21. Vitamin D can be 
obtained through the diet or it is  
synthesized in the skin after exposure to 
the sun. However, because few foods 
provide a natural source of vitamin D38 
and because fortification of foods with 
vitamin D is often unreliable39, skin 
synthesis is thought to constitute the 
major source. In addition, levels of 
vitamin D and its main circulating 
metabolite, 25 OH-D, are under the 
predominant influence of solar 
ultraviolet B radiation (wavelength 290  
to 315 nm).39. 
In this work, diabetics differ from non- 
diabetics to be more prone to develop 
vitamin D insufficiency in the face of 
low vitamin D intake if not helped by 
increased sun exposure (Tables 1,2 & 
Figure 2). There must be some intrinsic 
factors unique to type 2 diabetes that 
could be used as predictors for 
developing this state of 
hypovitaminosis. The significant higher 
age, BMI, glycemic indices and 
frequency of diabetic complications in 
the group with vitamin D insufficiency, 
besides the negative association 
between 25 OH-D level and BMI and 
glycemic indices in our diabetics could 
represent the answer.  The inverse 
relation between serum 25 OH-D and 
BMI has been observed previously in 
type 2 diabetes25, postmenopausal 
women40, elderly people41, and younger 
obese subjects42. Need and associates40 
suggested that the inverse relation 
between 25 OH-D and BMI is due a 
larger body pool of vitamin D and 25 
OH-D or slower saturation and 
mobilization of these compounds from 
adipose tissue (or both). Once vitamin D 
is synthesized in the skin or ingested, it 
is deposited in body fat stores, making it 
less bioavailable to people with large 
stores of body fat making obesity a risk 
factor for vitamin D deficiency42. The
influence of poor metabolic control on 
lowering 25 OH-D level was detected by 
other researchers. 
In Need's study40 fasting serum glucose 
increased as 25(OH)D levels fell 
throughout the range of serum 25(OH)D 
measured but the greatest increase was 
observed in those with vitamin D 
insufficiency. The association between 
Vitamin D insufficiency and diabetic 
complications seems to be strong but 
complex. Some researchers claim that 
vitamin D insufficiency predispose to 
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complications mainly cardiovascualr 
events10. More studies are necessary to 
determine whether vitamin D 
insufficiency predicts the occurrence of 
cardiovascular disease, and to 
determine whether vitamin D 
supplementation would be protective 
against cardiovascular disease in Type 2 
Diabetics.  
 
Conclusion 
 
Our findings, confirm some previous 
evidence demonstrating that vitamin D 
insufficiency is highly prevalent in 
postmenopausal women with type 2 
diabetes increasing their high risk for 
fragility fractures. The associated 
functional hypoparathyroidism leads to 
low bone turn-over, one of the 
underlying mechanisms for the so called 
diabetic osteopenia. The increased age 
and weight, lower sun exposure, poor 
metabolic control and presence of 
vascular complications seem to be the 
predictors of this state. The significance 
of these findings seems to be important 
as this state of hypoviataminosis D 
could lead to worsening of diabetic 
control. However, our findings need to 
be consolidated by larger study as there 
are some limitations in this study.  
 
Because our study was a cross-sectional 
one, the causative nature of the 
associations cannot be established.  
Additionally, 24,25 and 1 ,25(OH)D 
were not measured  in this study. 
Additional studies are needed to clarify 
the association between vitamin D 
insufficiency and type 2 diabetes 
whether a cause or a consequence and 
also to study effect of vitamin D 
repletion on diabetic status. Further 
evidence based clinical research is 
required to confirm our findings. 
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